Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma

Charles B. Simone, John C. Morris, Donn M. Stewart, Nicole E. Urquhart, John E. Janik, Robert J. Kreitman, Elena Lita, Kevin Conlon, Gilian Wharfe, Thomas A. Waldmann, Aradhana Kaushal

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Human T-cell leukemia virus type 1 - associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; P = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control acrossATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.

Original languageEnglish (US)
Pages (from-to)1816-1819
Number of pages4
JournalBlood
Volume120
Issue number9
DOIs
StatePublished - Aug 30 2012

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
T-cells
Radiotherapy
Survival
Deltaretrovirus
Skin
Radiation Oncology
Oncology
Chemotherapy
Viruses
Toxicity
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Simone, C. B., Morris, J. C., Stewart, D. M., Urquhart, N. E., Janik, J. E., Kreitman, R. J., ... Kaushal, A. (2012). Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Blood, 120(9), 1816-1819. https://doi.org/10.1182/blood-2012-01-401349

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. / Simone, Charles B.; Morris, John C.; Stewart, Donn M.; Urquhart, Nicole E.; Janik, John E.; Kreitman, Robert J.; Lita, Elena; Conlon, Kevin; Wharfe, Gilian; Waldmann, Thomas A.; Kaushal, Aradhana.

In: Blood, Vol. 120, No. 9, 30.08.2012, p. 1816-1819.

Research output: Contribution to journalArticle

Simone, CB, Morris, JC, Stewart, DM, Urquhart, NE, Janik, JE, Kreitman, RJ, Lita, E, Conlon, K, Wharfe, G, Waldmann, TA & Kaushal, A 2012, 'Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma', Blood, vol. 120, no. 9, pp. 1816-1819. https://doi.org/10.1182/blood-2012-01-401349
Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ et al. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Blood. 2012 Aug 30;120(9):1816-1819. https://doi.org/10.1182/blood-2012-01-401349
Simone, Charles B. ; Morris, John C. ; Stewart, Donn M. ; Urquhart, Nicole E. ; Janik, John E. ; Kreitman, Robert J. ; Lita, Elena ; Conlon, Kevin ; Wharfe, Gilian ; Waldmann, Thomas A. ; Kaushal, Aradhana. / Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. In: Blood. 2012 ; Vol. 120, No. 9. pp. 1816-1819.
@article{6163501df46e45ddb9c3832775d40ba8,
title = "Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma",
abstract = "Human T-cell leukemia virus type 1 - associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0{\%} (nodal 37.5{\%} vs cutaneous 50.0{\%}; P = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0{\%}). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control acrossATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.",
author = "Simone, {Charles B.} and Morris, {John C.} and Stewart, {Donn M.} and Urquhart, {Nicole E.} and Janik, {John E.} and Kreitman, {Robert J.} and Elena Lita and Kevin Conlon and Gilian Wharfe and Waldmann, {Thomas A.} and Aradhana Kaushal",
year = "2012",
month = "8",
day = "30",
doi = "10.1182/blood-2012-01-401349",
language = "English (US)",
volume = "120",
pages = "1816--1819",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma

AU - Simone, Charles B.

AU - Morris, John C.

AU - Stewart, Donn M.

AU - Urquhart, Nicole E.

AU - Janik, John E.

AU - Kreitman, Robert J.

AU - Lita, Elena

AU - Conlon, Kevin

AU - Wharfe, Gilian

AU - Waldmann, Thomas A.

AU - Kaushal, Aradhana

PY - 2012/8/30

Y1 - 2012/8/30

N2 - Human T-cell leukemia virus type 1 - associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; P = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control acrossATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.

AB - Human T-cell leukemia virus type 1 - associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; P = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control acrossATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.

UR - http://www.scopus.com/inward/record.url?scp=84865780225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865780225&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-401349

DO - 10.1182/blood-2012-01-401349

M3 - Article

C2 - 22730536

AN - SCOPUS:84865780225

VL - 120

SP - 1816

EP - 1819

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -